Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9Y289

UPID:
SC5A6_HUMAN

ALTERNATIVE NAMES:
Solute carrier family 5 member 6

ALTERNATIVE UPACC:
Q9Y289; B2RB85; D6W549; Q969Y5

BACKGROUND:
The Sodium-dependent multivitamin transporter, identified as Solute carrier family 5 member 6, mediates the uptake of vital nutrients including pantothenate, biotin, and lipoate, essential for cellular function and integrity. Its unique mechanism involves a Na+-coupled symport process, leveraging an electrochemical gradient for efficient nutrient transport. This protein's role extends beyond nutrient absorption in the gut, contributing to the biotin and pantothenate transport across the blood-brain barrier, crucial for brain health.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of the Sodium-dependent multivitamin transporter could open doors to potential therapeutic strategies. Its direct involvement in diseases such as Sodium-dependent multivitamin transporter deficiency and biotin-responsive Peripheral motor neuropathy underscores its importance in developing targeted treatments that could alleviate symptoms and improve quality of life for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.